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Identity 
Other names: MGC26465 




Human FUT8 gene is located on chromosome 14q23.3 
(Yamaguchi et al., 1999). This gene encompasses 
approximately 333 kb and contains nine exons with 
coding regions and three 5'-untranslated exons 
(Yamaguchi et al., 2000; Martinez-Duncker et al., 
2004). 
Transcription 
Some splicing variants of the 5'-untranslated region 
arise in a developmental stage-specific and tissue-
specific manner (Martinez-Duncker et al., 2004). At 
least three different promoters appear to be functio al 
in regulating the expression of the FUT8 gene. Three 
transcripts with different 5'-untranslated regions have 
been identified. With respect to coding region, four 
variants were reported to encode polypeptides 
containing 575, 446, 308 and 169 amino acid residue. 
The 575 residue protein is a fully active alpha1,6-
fucosyltransferase, which was first of the variants to be 
identified.  
 
Figure 1. Genomic organization of human FUT8 gene. Exons are represented by vertical bars. Exons denoted by ATG or TAA contain 
start and stop codons, respectively. These exons also have a part of the noncoding region. 
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Figure 2. Protein structure of FUT8. CT and TM denote the cytoplasmic tail and the transmembrane domain, respectively. I, II and III 
represent the conserved motifs in alpha1,2-, alpha1,6- and protein O-fucosyltransferases. 
 
The other variants have not yet been examined for 
enzymatic activity and biological function. The 308 
amino acid variant is known to be expressed in the 
retina (Yamaguchi et al., 2000). 
Protein 
Description 
FUT8 was purified and cloned as a cDNA from porcine 
brain and a human gastric cancer cell line (Uozumi et 
al., 1996, Yanagidani et al., 1997). Human FUT8 is 
comprised of 575 amino acids, with a calculated 
molecular weight of 66516. FUT8 contains no N-
glycosylation sites. This enzyme belongs to the GT23 
family of the CaZY classification. The structual 
analysis of a transmembrane domain-truncated form of 
FUT8 showed that the enzyme consists of a catalytic 
domain, an N-terminal coiled-coil domain and a C-
terminal SH3 domain (Ihara et al., 2007). The catalytic 
domain was structurally classfied as a member of the 
GT-B group of glycosylatransferases. 
Expression 
FUT8 gene is widely expressed in human tissues 
(Martinez-Duncker et al., 2004). The FUT8 gene is 
expressed at relatively high levels in the brain, 
placenta, lung, stomach, small intestine and jejunum, 
while pancreas, uterus, kidney and urinary bladder 
exhibit moderate expression. The FUT8 gene is weakly 
expressed in the heart, ileum, colon and spleen. On the 
other hand, the expression is not detectable in the 
normal liver (Miyoshi et al., 1997). 
Localisation 
FUT8 is a typical type II membrane protein and is 
localized in the Golgi apparatus. 
 
Figure 3. The reaction catalysed by FUT8. 
Function 
FUT8 catalyzes the transfer of a fucose residue from 
GDP-fucose to the reducing terminal GlcNAc of Asn-
linked oligosaccharide (N-glycan) via an alpha1.6-
linkage (Figure 3). The resulting fucosyl residue is 
often refered to as a core fucose. The reaction does n t 
require any divalent cations or cofactors. The deletion 
of the FUT8 gene in mice leads to severe phenotypes 
that exhibit growth retardation, lung emphysema and
death during postnatal development (Wang et al., 
2005). As has been clearly shown in studies using 
knockout mice, the lack of core fucosylation resulted in 
the biological activities of various proteins to be 
perturbed (Taniguchi et al., 2006; Takahashi et al., 
2009). Examples of this include the TGF-beta1 receptor 
(Wang et al., 2005), EGF receptor (Wang et al., 2006), 
VEGF receptor-2 (Wang et al., 2009), LRP-1 (Lee et 
al., 2006), E-cadherin (Osumi et al., 2009), alpha3beta1 
integrin (Zhao et al., 2006), VCAM and alpha4beta1 
integrin (Li et al., 2008). The binding affinity of the 
core fucose-deleted TGF-beta receptor to TGF-beta 1 is 
diminished in fut8-null mice, resulting in the 
downregulation of TGF-beta 1 signaling (Wang et al., 
2005). The unusual overexpression of matrix 
metalloproteinases such as MMP-12 and MMP-13 is 
associated with the impaired receptor function, and has 
been proposed to cause the lung-destructive 
phenotypes. The EGF receptor in fut8 null mice is also 
affected in terms of its binding affinity to EGF and 
EGF-induced phoshorylation (Wang et al., 2006). 
These studies strongly suggest that FUT8 and core 
fucose structures regulate the receptor function. 
In addition, core fucosylation was reported to be 
involved in antibodydependent cellular cytotoxicity 
(ADCC) (Shields et al., 2002; Shinkawa et al., 2003). 
The lack of core fucose of N-glycan in the Fc region of 
the IgG1 molecule enhances ADCC activity up to 50-
100-fold. This discorvery promises to be useful in the
development of antibody therapy in cancer treatment. 
Homology 
The sequence identities between human FUT8 and 
other organisms are as follows : 
Chimpangee (100%), Dog (97.7%), Cow (97.5%), Pig 
(95.6%), Rat (96.6%), Mouse (96.5%), Chicken 
(93.9%), Clawed frog (90.3%), Zebrafish (79.5%), 
Takifugu (80.2%), Tetraodon (79.8%), Sea squirt 
(23.2%), Fruit fly (43.7%), C. elegans (34.8%). 
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Eight cysteine residues in the catalytic domain are
conserved among these species, except for ciona (Ihara 
et al., 2007). 
FUT8 contains three short regions that are highly 
conserved in FUT8, alpha1,2-, bacterial alpha1,6-, and
protein O-fucosyltransferases (Oriol et al., 1999; 
Takahashi et al., 2000a; Chazalet et al., 2001; 
Martinez-Duncker et al., 2003). The structual analysis 
has shown that these regions are located adjacent to o e 
another in the Rossmann fold of FUT8 (Ihara et al., 
2007). In addition, the C-terminal SH3 domain of 
FUT8 is structually similar to the typical SH3 domain 
that is found in many proteins. 
Mutations 
Note 
One frame-shit mutation and 4 substitution mutants 
have been identified to date in various SNPs of the 
FUT8 gene. The frame shift mutant is due to the 
insertion of a T at position 2 of the codon for Val-85, 
resulting in 85-VLEEQLVK-92 being change to 85-
VFRRAACter-92. The four substitution mutants are 
K101Q, L153V, E181G and T267K. These mutants are 
due to A being substituted by C at position 1 of codon 
101, C to G at position 1 of codon 153, A to G at 
position 2 of codon 181, and C to A at posision 2 of 
codon 267, respectively. Effects of these substitutions 
on enzymatic activity are not currently known. 
Implicated in 
Hepatocellular carcinoma (HCC) 
Note 
It is well known that the core fucosylation of alpha-
fetoprotein (AFP) is implicated in the development of 
HCC. AFP is a major fetal plasma protein, and its 
expression is elevated in hepatic diseases such as HCC,
hepatitis and liver cirrhosis (Alpert et al., 1968; 
Ruoslahti et al., 1974). The AFP-L3 fraction was 
identified as the core-fucosylated isoform of AFP. The 
elevation in serum and liver tissue was found to be 
specific to HCC, but was not observed in other liver 
diseases (Taketa, 1990; Aoyagi, 1995; Miyoshi et al., 
1999). 
Thus, it appears that AFP-L3 could be used as a marker 
for HCC. The FUT8 gene is not expressed in the 
normal adult liver, but is highly expressed in HCC 
tissue. Surprisingly, however, such an elevation was 
also observed in liver cirrhosis in spite of the absence 
of a concomitant increase in AFP-L3 levels (Noda et 
al., 1998). This discrepancy can be attributed to the 
difference in the synthesis of GDP-fucose, a glycosl 
donor substrate for fucosyltransferases, including 
FUT8, and by the altered intracellular sorting of 
fucosylated glycoproteins in hepatic cells. Because the 
intracellular concentration of GDP-fucose is higher in 
HCC, as compared to a normal liver, chronic hepatitis 
and liver cirrhosis, this increase would be expected to 
facilitate core fucosyltion of AFP (Noda et al., 2003). 
Core fucosylation appears to serve as a sorting signal 
for a glycoprotein to be directed to the bile, as revealed 
by the predominant distribution of fucosylated 
glycoproteins in bile rather than serum (Nakagawa et 
al., 2006). In fact, the levels of alpha-antitrypsin and 
alpha1-acid glycoprotein, both of which are fucosylated 
glycoproteins, are quite low in the bile of Fut8-null 
mice. The loss of polarity in cancer cells is likely to 
impair the regulated sorting, thus allowing abnormal 
secretion into the serum. 
Prognosis 
AFP-L3-positive HCC patients were reported to show a 
poor prognosis (Yamashita et al., 1996). 
Ovarian cancer 
Note 
FUT8 activity and mRNA levels are highly and 
specifically elavated in cases of ovarian serous 
adenocarcinoma, as compared to nomal ovary and other 
types of epithelial ovarian carcinoma (Takahashi et al., 
2000b). In addition, core fucosylation levels in 
glycoproteins is also significantlly increased in cases of 
serous adenocarcinoma tissues. 
Thyroid cancer 
Note 
The overexpression of FUT8 occurs in 33.3% of cases 
of papillary carcinoma of the thyroid (Ito et al., 2003), 
although FUT8 was not expressed in normal follicular 
cells. This overexpression was also shown to be 
correlated with tumor size and lymph node metastasi. 
These phenomena were not observed in cases of 
follicular carcinoma and anaplastic carcinoma. 
Pancreatic cancer 
Note 
Haptoglobin was identified as a highly fucosylated 
glycoprotein in the serum of patients with pancreatic 
cancer (Okuyama et al., 2006). The increment of 
fucosylated haptoglobin was observed in pancreatic 
cancer rather than other diseases such as HCC, liver 
cirrhosis, gastric cancer and colon cancer, and also
appeared to be correlated with the clinical stage. 
Structural analyses using lectin blotting and mass 
spectrometry showed that core fucosylation as well as 
alpha1,3/4-fucosylation is increased in haptoglobin 
from the serum of such patients. In addition, it was 
shown that interleukin 6 expressed in pancreatic can er 
is a possible inducing factor for increasing the 
production of fucosylated haptoglobin in the liver 
(Narisada et al., 2008). 
Colorectal cancer 
Note 
The enzymatic activity and protein expression of FUT8 
were increased in tumor tissues of human colorectal 
carcinoma, but not in healthy tissues (Muinelo-Romay 
et al., 2008). This increment was well observed in cases 
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of male, polypoid growth, no regional lymph node 
metastasis and early clinical stage. In addition, 
immunohistochemical examination has demonstrated 
that FUT8 is expressed at higher levels in tumor tissues 




Fucosylation is known to be increased in cystic 
fibrosis. The alpha1,6-fucosylation of a membrane 
glycoprotein is elevated in cystic fibrosis fibroblast 
(Wang et al., 1990). 
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